Observational Study of the Use of 8% Capsaicin Patch in Children 0 to 18 Years Old

NCT ID: NCT05299294

Last Updated: 2024-09-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-12

Study Completion Date

2027-09-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients aged less than 18-y with validated 8% capsaicin patch treatment in routine healthcare will be offered to participate the study. If they accept it as well as their parents, they will be included in the study .

Medical data will be recorded and at home, the child or his family will collect pain assessment data.

Tolerance will be monitored at home by phone call from investigational team every 24 hours until normalization. (Less than 24 hours for 75%, 100% to 72 hours on unpublished personal series.) Children will be assessed via scales at inclusion and 1-month, 3-month and 6-month.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Children and teenagers aged less than 18-y, with chronic localized neuropathic pain, may be treated by capsaicin 8% patch. If this indication is validated in pediatric chronic pain consultation, they will be offered to participate the study. If they accept it as well as their parents, they will be included in the study.

Treatment application will follow recommendations and be realized in out patient clinic with trained nurses.

Tolerance will be assessed by phone call every 24 Hours by investigational team until normalization. Expected duration is less than 24 Hours for 75% patients and 100 % at 72 Hours, from unpublished personal data.

Efficacy will be monitored with usual pain and neuropathic pain tools, adapted to age and cognitive capacities, one month after application.

Treatment may be done three times if needed with a three month interval between each capsaicin patch application.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuropathic Pain Chronic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Data collection

Collecting data on children receiving capsaicine 8% patch for localized neuropathic pain

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* chronic localized neuropathic pain
* capsaicin 8% patch treatment indication validated in a pediatric chronic pain center
* agreement for participation by child and parents

Exclusion Criteria

* already treated with capsaicin 8% patch in the same body area
* already treated in the same study in an other investigation center
* non willing to participate or parents not willing participation to the study
Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondation de France

OTHER

Sponsor Role collaborator

Fondation Apicil

OTHER

Sponsor Role collaborator

University Hospital, Brest

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philippe J Le Moine, MD

Role: PRINCIPAL_INVESTIGATOR

CHRU of Brest

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Angers

Angers, France, France

Site Status NOT_YET_RECRUITING

CHU Bordeaux

Bordeaux, France, France

Site Status RECRUITING

CHR Bourg en Bresse

Bourg-en-Bresse, France, France

Site Status NOT_YET_RECRUITING

CHU de Brest

Brest, France, France

Site Status RECRUITING

CHU Caen

Caen, France, France

Site Status RECRUITING

CHU Grenoble

Grenoble, France, France

Site Status NOT_YET_RECRUITING

CHU Lille

Lille, France, France

Site Status RECRUITING

CHU Limoges

Limoges, France, France

Site Status NOT_YET_RECRUITING

CHU Marseille

Marseille, France, France

Site Status RECRUITING

CHU Montpellier

Montpellier, France, France

Site Status RECRUITING

CHU Nancy

Nancy, France, France

Site Status NOT_YET_RECRUITING

CHU Nantes

Nantes, France, France

Site Status RECRUITING

CHU Robert Debré

Paris, France, France

Site Status NOT_YET_RECRUITING

CHU Trousseau

Paris, France, France

Site Status NOT_YET_RECRUITING

CHU Rouen

Rouen, France, France

Site Status RECRUITING

CHRU Strasbourg

Strasbourg, France, France

Site Status RECRUITING

CHU Toulouse

Toulouse, France, France

Site Status RECRUITING

Institut Gustave Roussy

Villejuif, France, France

Site Status RECRUITING

CHU d'Amiens

Amiens, , France

Site Status NOT_YET_RECRUITING

CHU Lyon

Lyon, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Philippe J Le Moine, MD

Role: CONTACT

+33298223956

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Petronela Rachieru Sourisseau, MD

Role: primary

+33241355741

Sylvie Berciaud, MD

Role: primary

+33557820194

Clémence Dal-Col, MD

Role: primary

+33474454357

Philippe J LE MOINE, MD

Role: primary

+33298223956

Alexandra Desdoits, MD

Role: primary

+33231064486

Mariel Cartal, MD

Role: primary

+33476767987

Justine Avez-Couturier, MD

Role: primary

+33320444671

Christophe Piguet, MD

Role: primary

+33555056801

Cécile Mareau, MD

Role: primary

+33491386302

Frédéri Bernard, MD

Role: primary

Ludovic Mansuy, PHD

Role: primary

+33383154734

Marine Letellier

Role: primary

+33240083610

Esther Soyeux, MS

Role: primary

+33140034102

Barbara Tourniaire, MD

Role: primary

+33144737392

Alice Petit-Ledo, MD

Role: primary

+33232885898

Mathieu REBERT, MD

Role: primary

Agnès Suc, MD

Role: primary

+33534558661

Marie-Anne Sevèque Sevèque, MD

Role: primary

+33142114433

Sandrine SORIOT-THOMAS

Role: primary

+33322087997

Sabine Simonin, MD

Role: primary

+33472118866

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

29BRC21.0184 (CAPSULE)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.